JP2013505983A - Ｓ１ｐ受容体モジュレーターの投与計画 - Google Patents

Ｓ１ｐ受容体モジュレーターの投与計画 Download PDF

Info

Publication number
JP2013505983A
JP2013505983A JP2012532119A JP2012532119A JP2013505983A JP 2013505983 A JP2013505983 A JP 2013505983A JP 2012532119 A JP2012532119 A JP 2012532119A JP 2012532119 A JP2012532119 A JP 2012532119A JP 2013505983 A JP2013505983 A JP 2013505983A
Authority
JP
Japan
Prior art keywords
patient
agonist
receptor modulator
administration
monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012532119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505983A5 (https=
Inventor
ブルトン，クレイグ
ブルタン，パスカル
ダヴィッド，オリヴィエ
ヴェラ，アナ デ
デュモルティエ，トマ
ハント，イレーヌ
シュムーダー，ロバート
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013505983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013505983A publication Critical patent/JP2013505983A/ja
Publication of JP2013505983A5 publication Critical patent/JP2013505983A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
JP2012532119A 2009-09-29 2010-09-20 Ｓ１ｐ受容体モジュレーターの投与計画 Withdrawn JP2013505983A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24670609P 2009-09-29 2009-09-29
US61/246,706 2009-09-29
US25832909P 2009-11-05 2009-11-05
US61/258,329 2009-11-05
US30799210P 2010-02-25 2010-02-25
US61/307,992 2010-02-25
US35202910P 2010-06-07 2010-06-07
US61/352,029 2010-06-07
PCT/US2010/049441 WO2011041146A2 (en) 2009-09-29 2010-09-20 Dosage regimen of an s1p receptor modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016061356A Division JP2016155840A (ja) 2009-09-29 2016-03-25 Ｓ１ｐ受容体モジュレーターの投与計画

Publications (2)

Publication Number Publication Date
JP2013505983A true JP2013505983A (ja) 2013-02-21
JP2013505983A5 JP2013505983A5 (https=) 2013-10-31

Family

ID=43759693

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012532119A Withdrawn JP2013505983A (ja) 2009-09-29 2010-09-20 Ｓ１ｐ受容体モジュレーターの投与計画
JP2016061356A Withdrawn JP2016155840A (ja) 2009-09-29 2016-03-25 Ｓ１ｐ受容体モジュレーターの投与計画
JP2018116214A Active JP7185426B2 (ja) 2009-09-29 2018-06-19 Ｓ１ｐ受容体モジュレーターの投与計画
JP2020133934A Pending JP2020203892A (ja) 2009-09-29 2020-08-06 Ｓ１ｐ受容体モジュレーターの投与計画
JP2023052843A Pending JP2023093482A (ja) 2009-09-29 2023-03-29 Ｓ１ｐ受容体モジュレーターの投与計画

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016061356A Withdrawn JP2016155840A (ja) 2009-09-29 2016-03-25 Ｓ１ｐ受容体モジュレーターの投与計画
JP2018116214A Active JP7185426B2 (ja) 2009-09-29 2018-06-19 Ｓ１ｐ受容体モジュレーターの投与計画
JP2020133934A Pending JP2020203892A (ja) 2009-09-29 2020-08-06 Ｓ１ｐ受容体モジュレーターの投与計画
JP2023052843A Pending JP2023093482A (ja) 2009-09-29 2023-03-29 Ｓ１ｐ受容体モジュレーターの投与計画

Country Status (18)

Country Link
US (9) US20120264719A1 (https=)
EP (4) EP3061449A1 (https=)
JP (5) JP2013505983A (https=)
KR (1) KR20120083442A (https=)
CN (2) CN103933570A (https=)
AU (2) AU2010101513B4 (https=)
BR (1) BR112012006957A2 (https=)
CA (2) CA2773330C (https=)
IL (2) IL218486A0 (https=)
MA (1) MA33691B1 (https=)
MX (1) MX2012003740A (https=)
NZ (1) NZ598534A (https=)
PH (2) PH12012500520A1 (https=)
RU (1) RU2012117563A (https=)
SG (4) SG10201913361RA (https=)
TN (1) TN2012000104A1 (https=)
WO (1) WO2011041146A2 (https=)
ZA (2) ZA201201678B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530835A (ja) * 2011-10-21 2014-11-20 ノバルティスアーゲー Ｓ１ｐ受容体モジュレーターまたはｓ１ｐ受容体アゴニストのための投薬量レジメン
JP2017510607A (ja) * 2014-04-10 2017-04-13 ノバルティス アーゲー Ｓ１ｐ調節剤即時放出投与レジメン

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
EP3502236B1 (en) * 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CA2851525A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
BR112015020140A8 (pt) * 2013-04-04 2019-11-19 Novartis Ag ácido 1-{4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil}-azetidina-3-carboxílico, seus usos e combinação farmacêutica
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN116784795A (zh) 2017-11-30 2023-09-22 思维有限公司 用于评估与多发性硬化症相关的神经功能受损的方法
WO2020214513A1 (en) * 2019-04-17 2020-10-22 Pear Therapeutics, Inc. Electronic devices and methods for treatment of depressive symptoms, depressive disorders utilizing digital therapies
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158847A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158845A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158843A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158841A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158839A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158844A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
EP4164605A4 (en) * 2020-06-11 2024-06-19 The Trustees of Columbia University in the City of New York METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH FINGOLIMOD, A SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR AND DERIVATIVES THEREOF
CN119997878A (zh) * 2022-07-28 2025-05-13 思维有限公司 使用视觉刺激、药物或治疗来鉴定疾病特有的眼球运动模式

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231560B1 (en) * 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
PT1505959E (pt) 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0211261D0 (en) * 2002-05-16 2002-06-26 Novartis Ag Organic compounds
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
EP1644367B1 (en) 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
AU2004271804B2 (en) 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
KR20070085465A (ko) 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2007061274A (ja) * 2005-08-30 2007-03-15 Transcutaneous Technologies Inc センサからの副作用情報による投薬停止システムを備えたイオントフォレーシス装置
EP1905434A1 (en) 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
TW201028143A (en) 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530835A (ja) * 2011-10-21 2014-11-20 ノバルティスアーゲー Ｓ１ｐ受容体モジュレーターまたはｓ１ｐ受容体アゴニストのための投薬量レジメン
JP2017510607A (ja) * 2014-04-10 2017-04-13 ノバルティス アーゲー Ｓ１ｐ調節剤即時放出投与レジメン

Also Published As

Publication number Publication date
EP2482810A2 (en) 2012-08-08
SG10201913361RA (en) 2020-03-30
ZA201404270B (en) 2014-12-23
JP7185426B2 (ja) 2022-12-07
US11759436B2 (en) 2023-09-19
CA3129729A1 (en) 2011-04-07
US20120264719A1 (en) 2012-10-18
CA2773330A1 (en) 2011-04-07
PH12017501495A1 (en) 2018-07-02
JP2020203892A (ja) 2020-12-24
JP2016155840A (ja) 2016-09-01
RU2018118645A3 (https=) 2021-09-13
TN2012000104A1 (en) 2013-09-19
US20140187516A1 (en) 2014-07-03
MX2012003740A (es) 2012-04-30
WO2011041146A3 (en) 2011-06-03
WO2011041146A2 (en) 2011-04-07
US20180263930A1 (en) 2018-09-20
RU2012117563A (ru) 2013-11-10
MA33691B1 (fr) 2012-10-01
CN102548579A (zh) 2012-07-04
EP3047848A1 (en) 2016-07-27
RU2018118645A (ru) 2018-11-05
CA2773330C (en) 2021-11-02
US20260053756A1 (en) 2026-02-26
JP2018172401A (ja) 2018-11-08
US10543179B2 (en) 2020-01-28
ZA201201678B (en) 2016-01-27
JP2023093482A (ja) 2023-07-04
NZ598534A (en) 2014-03-28
EP3831371A1 (en) 2021-06-09
EP3061449A1 (en) 2016-08-31
BR112012006957A2 (pt) 2016-06-14
IL250439A0 (en) 2017-03-30
PH12012500520A1 (en) 2012-10-22
CN103933570A (zh) 2014-07-23
AU2010101513A6 (en) 2014-07-10
SG10201902152XA (en) 2019-04-29
US20200222338A1 (en) 2020-07-16
KR20120083442A (ko) 2012-07-25
US20230086687A1 (en) 2023-03-23
US20160256416A1 (en) 2016-09-08
AU2010101513B4 (en) 2016-05-05
US20170304226A1 (en) 2017-10-26
IL218486A0 (en) 2012-04-30
US20180263929A1 (en) 2018-09-20
AU2010300919A1 (en) 2012-03-22
SG178987A1 (en) 2012-04-27
SG10201406168RA (en) 2014-11-27
AU2010101513A4 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
JP7185426B2 (ja) Ｓ１ｐ受容体モジュレーターの投与計画
AU2023204098A1 (en) Dosage regimen of an S1P receptor modulator
AU2015101630A4 (en) Dosage regimen of an S1P receptor modulator
RU2776152C2 (ru) Режим дозирования модулятора рецептора s1p
HK40049428A (en) Dosage regimen of an s1p receptor modulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141211

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160406